Xanthoma

01Pathophysiology

Xanthomas arise from the extravascular deposition of lipids within macrophages in the dermis, subcutaneous tissue, or tendons. The process begins when circulating lipoproteins, particularly LDL cholesterol or triglyceride-rich remnant particles, accumulate in tissues at concentrations exceeding the capacity of normal metabolic clearance.

Once deposited, these lipoproteins undergo oxidative modification. Tissue macrophages then engulf the modified lipoproteins through scavenger receptors (CD36, SR-A), which, unlike the LDL receptor, are not downregulated by intracellular cholesterol levels. This means macrophages continue to ingest lipid without a feedback mechanism to stop uptake. The result is the formation of foam cells, which are lipid-engorged macrophages that aggregate and become visible as yellowish deposits.

The type and location of the xanthoma directly reflect the class of lipoprotein that is elevated. For example, markedly elevated triglycerides (often above 1000 mg/dL) cause rapid dermal infiltration leading to eruptive xanthomas, while chronically elevated LDL causes slow tendon infiltration leading to tendinous xanthomas. This is why the morphology and distribution of a xanthoma serve as a clinical clue to the underlying lipid disorder.

The yellowish color is due to the carotenoid and lipid content within the foam cells. Importantly, xanthomas themselves are not dangerous, but they are cutaneous markers of systemic dyslipidemia, which carries a high risk for premature atherosclerotic cardiovascular disease (ASCVD) and, in the case of severe hypertriglyceridemia, acute pancreatitis.

02Classification and Clinical Manifestation

03Diagnostic Workup

The fasting lipid panel is the best initial test for any patient presenting with xanthomas. This test alone will often point toward the category of dyslipidemia. If LDL is disproportionately elevated (often >300 mg/dL) with tendinous xanthomas, the clinical picture strongly suggests Familial Hypercholesterolemia. If triglycerides are severely elevated (>1000 mg/dL) with eruptive xanthomas, the concern shifts to Type I or Type V hyperlipidemia and the immediate risk of pancreatitis.

If Type III dysbetalipoproteinemia is suspected based on palmar crease xanthomas and a lipid panel showing both cholesterol and triglycerides elevated to a similar degree (typically 300-600 mg/dL for each), the next step is ApoE genotyping to look for homozygous ApoE2/E2. Lipoprotein electrophoresis showing a broad-beta band is also characteristic.

If the diagnosis is clinically ambiguous, a skin biopsy serves as the most accurate confirmatory test. Histopathology shows collections of foamy histiocytes (foam cells) in the dermis, often accompanied by Touton giant cells, which are multinucleated giant cells with a ring of foamy cytoplasm surrounding a wreath of nuclei.

A workup for secondary causes of dyslipidemia should be performed in every case, as treating the underlying condition (hypothyroidism, uncontrolled diabetes, nephrotic syndrome, cholestasis) may resolve both the lipid abnormality and the xanthomas. For diffuse plane xanthomas without a clear lipid abnormality, serum protein electrophoresis (SPEP) and further hematologic evaluation are indicated to rule out a paraproteinemia or lymphoproliferative disorder.

04Management and Treatment

Acute stabilization is relevant only in the setting of eruptive xanthomas with severe hypertriglyceridemia (TG >1000 mg/dL), where the immediate concern is acute pancreatitis. The first step is strict dietary fat restriction (limit fat intake to 10-15% of total calories). If the patient is hospitalized, an insulin infusion can activate lipoprotein lipase and accelerate triglyceride clearance, even in non-diabetic patients. Heparin also releases lipoprotein lipase from endothelial surfaces but is used less commonly due to rebound effects.

For long-term management, the cornerstone is treating the underlying lipid disorder. In patients with elevated LDL (the most common exam scenario with tendinous xanthomas), high-intensity statin therapy is first-line. If the LDL goal is not reached, ezetimibe is added. For patients with Familial Hypercholesterolemia who remain above goal, PCSK9 inhibitors (evolocumab, alirocumab) represent the next escalation step and are particularly high-yield for exams. In homozygous FH with minimal LDL receptor activity, lomitapide (MTP inhibitor) or LDL apheresis may be required.

For hypertriglyceridemia, fibrates are the primary pharmacologic agent. Fenofibrate is preferred over gemfibrozil when used alongside a statin due to a lower risk of myopathy. Omega-3 fatty acids (icosapent ethyl 2 g PO BID) serve as adjunctive therapy for persistent hypertriglyceridemia and have demonstrated cardiovascular benefit.

Contraindications to note: Statins are contraindicated in pregnancy (teratogenic, Category X). Gemfibrozil combined with a statin significantly increases the risk of rhabdomyolysis and should be avoided; use fenofibrate instead. Fibrates should be used cautiously in patients with severe renal impairment (dose adjustment required for fenofibrate if GFR <30 mL/min).

With successful lipid-lowering therapy, most xanthomas gradually regress over months to years. Eruptive xanthomas resolve the fastest (often within weeks), while tendinous xanthomas may take much longer and sometimes persist despite optimal therapy.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The most common way students miss xanthoma questions is by failing to connect the subtype of xanthoma to the correct underlying lipid disorder, and then failing to identify the appropriate next step in management based on that connection.

Here is the pattern: the vignette describes a yellowish lesion in a certain location, and the question asks either "What is the most likely underlying condition?" or "What is the next best step?" Students who memorize xanthoma as a single entity will not be able to distinguish between an eruptive xanthoma on the buttocks (pointing toward severe hypertriglyceridemia and pancreatitis risk, where the next step is urgent triglyceride lowering) and a tendinous xanthoma on the Achilles tendon (pointing toward Familial Hypercholesterolemia, where the next step is high-intensity statin therapy and family screening).

Another frequent trap involves xanthelasma. Up to half of patients with xanthelasma have completely normal lipid levels, so the exam may present a patient with eyelid xanthomas and a normal lipid panel and ask what to do next. The answer is reassurance and cosmetic referral if desired, not statin therapy.

The third classic trap is palmar crease xanthomas. If the vignette describes yellowish discoloration within the palmar creases, this is considered pathognomonic for Type III dysbetalipoproteinemia, and the confirmatory step is ApoE genotyping (homozygous E2/E2). Students often miss this because they do not recognize palmar crease xanthomas as a distinct entity.

Finally, when eruptive xanthomas appear suddenly in a patient with diabetes or alcohol use, students sometimes jump to a dermatologic diagnosis. The core competency being tested is the ability to recognize eruptive xanthomas as a systemic metabolic emergency signal that demands checking triglycerides and assessing pancreatitis risk before addressing the skin findings.